<?xml version="1.0" encoding="UTF-8" standalone="yes"?><drugRecordOutput id="65391"><DrugName>cancer therapy, MDS</DrugName><DrugSynonyms><Name><Value>anti-mitotic cancer therapy, BPH Corporate</Value></Name><Name><Value>BPH-8</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>BPH-25</Value><Types><Type>Research Code</Type></Types></Name><Name><Value>HLS5 modulators (cancer), BPH Corporate</Value></Name><Name><Value>cancer therapy, MDS</Value></Name></DrugSynonyms><CompanyOriginator id="16842">University of Western Australia</CompanyOriginator><CompaniesSecondary><Company id="1031950">BPH Energy Ltd</Company><Company id="1044885">Molecular Discovery Systems</Company><Company id="16842">University of Western Australia</Company></CompaniesSecondary><CrossReferences><SourceEntity id="1031950" type="Company"><TargetEntity id="4295856881" type="organizationId">BPH Energy Ltd</TargetEntity></SourceEntity><SourceEntity id="1044885" type="Company"><TargetEntity id="5000090166" type="organizationId">Molecular Discovery Systems Ltd</TargetEntity></SourceEntity><SourceEntity id="16842" type="Company"><TargetEntity id="4298537889" type="organizationId">University of Western Australia</TargetEntity></SourceEntity><SourceEntity id="651" type="ciIndication"><TargetEntity id="576" type="siCondition"/></SourceEntity></CrossReferences><PhaseHighest id="NDR">No Development Reported</PhaseHighest><PhaseTerminated id="DR">Discovery</PhaseTerminated><IndicationsSecondary><Indication id="651">Cancer</Indication></IndicationsSecondary><ActionsPrimary><Action id="20043">TRIM35 gene modulator</Action></ActionsPrimary><ActionsSecondary><Action id="767">Cell cycle inhibitor</Action></ActionsSecondary><Technologies><Technology id="762">Small molecule therapeutic</Technology></Technologies><LastModificationDate>2019-01-28T06:01:50.000Z</LastModificationDate><ChangeDateLast>2019-01-28T00:00:00.000Z</ChangeDateLast><AddedDate>2010-01-19T15:34:10.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkID="1044885" linkType="Company"&gt;Molecular Discovery Systems&lt;/ulink&gt; (MDS) a spun out of &lt;ulink linkID="1031950" linkType="Company"&gt;BPH Energy&lt;/ulink&gt; (BPH)  (formerly &lt;ulink linkID="1031950" linkType="Company"&gt;BPH Corporate&lt;/ulink&gt;  and previously BioPharmica), under license from the &lt;ulink linkID="16842" linkType="Company"&gt;University of Western Australia&lt;/ulink&gt;, was investigating anti-mitotic agents targeting HLS5 (TRIM35), genetic marker of early  cancer, including BPH-8 and BPH-25, for the potential treatment of cancer  [&lt;ulink linkID="1068618" linkType="Reference"&gt;1068618&lt;/ulink&gt;], [&lt;ulink linkID="1068619" linkType="Reference"&gt;1068619&lt;/ulink&gt;], [&lt;ulink linkID="1566546" linkType="Reference"&gt;1566546&lt;/ulink&gt;], [&lt;ulink linkID="1875594" linkType="Reference"&gt;1875594&lt;/ulink&gt;]. In March 2013, proof-of-concept studies were ongoing [&lt;ulink linkID="1388020" linkType="Reference"&gt;1388020&lt;/ulink&gt;]. In March 2009, the company was seeking to outlicense the program [&lt;ulink linkID="1069465" linkType="Reference"&gt;1069465&lt;/ulink&gt;]. In July 2014, the development of the drug was presumed to be suspended  [&lt;ulink linkID="1565592" linkType="Reference"&gt;1565592&lt;/ulink&gt;]. In October 2015, development of drug was under indefinite suspension [&lt;ulink linkID="1875589" linkType="Reference"&gt;1875589&lt;/ulink&gt;]. In November 2016, this was still the case [&lt;ulink linkID="1875591" linkType="Reference"&gt;1875591&lt;/ulink&gt;]. However, no further development has since been reported.&lt;/para&gt;&lt;para&gt;In June 2014, MDS announced that the development was to be suspended, effective July 2014 taking to into careful consideration of general market  conditions and available resources[&lt;ulink linkID="1565592" linkType="Reference"&gt;1565592&lt;/ulink&gt;], [&lt;ulink linkID="1875589" linkType="Reference"&gt;1875589&lt;/ulink&gt;].&lt;/para&gt;&lt;/Summary&gt;</value></Summary><Preclinical><displayLabel>Preclinical</displayLabel><value>&lt;Preclinical&gt;&lt;para&gt;By March 2013, studies on BPH-8 had shown that the agents disrupted adhesions between vascular endothelial cells [&lt;ulink linkID="1388020" linkType="Reference"&gt;1388020&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By August 2009, an unspecified lead candidate had been identified with activity 1000-fold higher than the initial compound derived from a chemical library. In animals, high levels of this compound showed no toxicity. At that time, the company was planning preclinical testing. By that time, BPH-8 and BPH-25 had been shown to induce mitotic arrest and apoptosis by disturbing mitotic spindle function [&lt;ulink linkID="1069466" linkType="Reference"&gt;1069466&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By March 2009, pharmaceutical and functional characterization of that agents had shown them to have comparable activity to the most active existing anti-mitotic drugs [&lt;ulink linkID="1069465" linkType="Reference"&gt;1069465&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In February 2009, data reported at the Lorne Cancer Conference in Victoria, Australia, showed that HSl5 was downregulated in breast and ovarian cancers [&lt;ulink linkID="1069220" linkType="Reference"&gt;1069220&lt;/ulink&gt;]. Data presented in December 2009 at the ASH meeting in New Orleans, LA showed that HLS5 modulated levels of sumoylated GATA-1 [&lt;ulink linkID="1069223" linkType="Reference"&gt;1069223&lt;/ulink&gt;]. In September 2010, similar data were presented at The Society for Hematology and Stem Cells in Australia [&lt;ulink linkID="1131456" linkType="Reference"&gt;1131456&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;By September 2008, increased HSL5 expression in tumor cells had been shown to suppress tumor growth, and BioPharmica had screened a compound library and identified potential hits that were being validated [&lt;ulink linkID="1069219" linkType="Reference"&gt;1069219&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Preclinical&gt;</value></Preclinical><AdditionalInformation><displayLabel>Additional Information</displayLabel><value>&lt;AdditionalInformation&gt;&lt;para&gt;In September 2009, BioPharmica planned to conduct an IPO to spin-off its MDS subsidiary to focus on an anti-cancer therapeutic, presumed to be this program [&lt;ulink linkID="1063910" linkType="Reference"&gt;1063910&lt;/ulink&gt;], [&lt;ulink linkID="1068773" linkType="Reference"&gt;1068773&lt;/ulink&gt;]. In October 2009, the spin-off was expected to close in November 2009 [&lt;ulink linkID="1068867" linkType="Reference"&gt;1068867&lt;/ulink&gt;].&lt;/para&gt;&lt;para&gt;In August 2009, BioPharmica finalized a new  agreement with the University of Western Australia (UWA) for  tumor suppressor gene HLS5 research, under which BioPharmica would own 100% of UWA's HLS5 intellectual property. UWA would be eligible to receive royalties from any commercialized products, potentially including a commercially-targeted project  to generate an antimitotic  anticancer therapeutic [&lt;ulink linkID="1068618" linkType="Reference"&gt;1068618&lt;/ulink&gt;]. Since 2004, BioPharmica had been investing in the University's HLS5 project [&lt;ulink linkID="1068619" linkType="Reference"&gt;1068619&lt;/ulink&gt;].&lt;/para&gt;&lt;/AdditionalInformation&gt;</value></AdditionalInformation></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1044885">Molecular Discovery Systems</Company><Country id="AU">Australia</Country><DevelopmentStatus id="NDR" sortOrder="3">No Development Reported</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2018-05-17T00:00:00.000Z</StatusDate></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16842">University of Western Australia</Company><Country id="AU">Australia</Country><DevelopmentStatus id="OL" sortOrder="1">Outlicensed</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2009-08-10T00:00:00.000Z</StatusDate><Source id="1068618" type="PR"/></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1031950">BPH Energy Ltd</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2004-12-31T00:00:00.000Z</StatusDate><Source id="1068619" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1044885">Molecular Discovery Systems</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2006-12-31T00:00:00.000Z</StatusDate><Source id="1566546" type="CORPORATE"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1044885">Molecular Discovery Systems</Company><Country id="AU">Australia</Country><DevelopmentStatus id="S" sortOrder="6">Suspended</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2014-07-17T00:00:00.000Z</StatusDate><Source id="1565592" type="PR"/></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16842">University of Western Australia</Company><Country id="AU">Australia</Country><DevelopmentStatus id="DR" sortOrder="7">Discovery</DevelopmentStatus><Indication id="651">Cancer</Indication><StatusDate>2004-12-31T00:00:00.000Z</StatusDate><Source id="1068619" type="PR"/></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="GTGT-04652"><Name>TRIM35 gene</Name><SwissprotNumbers/></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1031950">BPH Energy Ltd</Company><CountAsPrincipalActive>2</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>2</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>4</CountTotal></Company><Company><Company id="1036109">Western Australian Institute for Medical Research</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1044885">Molecular Discovery Systems</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="14337">Australian Government</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="16842">University of Western Australia</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="10">Technology - Other Proprietary</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="11">Patent - Exclusive Rights</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type><Type><Type sortOrder="13">Drug - Funding</Type><CountActive>2</CountActive><CountInactive>0</CountInactive><CountTotal>2</CountTotal></Type></CountsByTypes><Deals><Deal id="129293" title="BioPharmica to acquire rights to UWA's HLS5 project and fund research"/><Deal id="131032" title="Scott Kirkbride Melanoma Research Centre to award grant to BPH for melanoma research"/><Deal id="131033" title="BPH Corporate to receive NH&amp;MRC Grant to support HLS5 research"/><Deal id="131300" title="BPH to use Molecular Discovery Systems' imaging technology to screen compounds for melanoma "/></Deals><PatentFamilies><PatentFamily id="69167" number="WO-2007115364" title="Transcription factor modulator"/><PatentFamily id="774479" number="WO-2007109857" title="Agent for the treatment of hormone-dependent disorders and uses thereof"/></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="14">Tentative</Type><Count>2</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="8">General interest</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="BPH Energy Ltd" id="1031950"/><CountAsOwner>2</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>2</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Molecular Discovery Systems" id="1044885"/><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="University of Western Australia" id="16842"/><CountAsOwner>0</CountAsOwner><CountAsThirdParty>1</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></drugRecordOutput>